

# **The Cancer Drug Resistance Company**

**Økonomisk Ugebrev Life Science, 21 April 2021**

**Bo Rode Hansen, President & CEO**





# Disclaimer

*This presentation, which should be understood to include these slides, their contents or any part of them, any oral presentation, any question or answer session and any written or oral materials discussed or distributed during a company presentation (the "Presentation"), has been prepared by Scandion Oncology A/S ("Scandion Oncology" or the "Company"), to be used solely for a company presentation. The information contained in the Presentation is provided solely for this purpose.*

*This Presentation does not constitute or form part of, and should not be construed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction. The Presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure. The Company has not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant securities laws of any state or other jurisdiction of the United States of America.*

*Certain information contained herein has been obtained from published sources prepared by other parties that the Company has deemed to be relevant and trustworthy. No representation or warranty, express or implied, is made by the Company as to the accuracy, completeness or verification of any information contained in this Presentation. The Company has not made any independent review of information based on public statistics or information from an independent third party regarding the market information that has been provided by such third party, the industry or general publications.*

*Statements in this Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Past performance does not guarantee or predict future performance. Moreover, the Company does not – to the extent this is not required by law - undertake any obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this Presentation.*

*This Presentation as well as any other information provided by or on behalf of the Company in connection herewith shall be governed by Danish law. The courts of Denmark, with the District Court of Copenhagen as the first instance, shall have exclusive jurisdiction to settle any conflict or dispute arising out of or in connection with this Presentation or related matters.*



**“Scandion Oncology is pursuing a major unmet need in cancer treatment, that is prevention or reversal of anticancer drug resistance. The mission of the company is clear and important”**



**RICHARD L. SCHILSKY, MD, FACP, FSCT, FASCO, former ASCO executive**

*Newly appointed member of Scandion Oncology’s  
Clinical Advisory Board*



The Cancer Drug Resistance Company



# Why Invest in Scandion Oncology?

## Targeting Cancer Drug Resistance

rapid peak sales can be reached given a combination therapy application

Scandion Oncology A/S is a clinical Phase II biotechnology company developing **first-in-class, oral, add-on drugs to revert resistance to existing anti-cancer therapies.**

**Targeting USD 37bn chemotherapy market growing at 12% annually**

## Well-documented Mechanisms of Action

enabling the company to target a wide variety of cancer indications

**Lead candidate, SCO-101, currently in clinical Phase II trial (CORIST) targeting metastatic chemotherapy resistant colorectal cancer. Data read-out from part 1 in Q2, 2021**

**A Phase Ib trial (PANTAX) targeting metastatic pancreatic cancer with expected data read-out in Q3-Q4, 2021**

## Experienced Leadership

track record of successfully developing biotechnology companies

Proven track-record of preclinical research, clinical trials and deal activities paves the way for **future commercial success whilst reducing execution risk**



The Cancer Drug Resistance Company

# Setting Pace for the Future

- **Progress in clinical pipeline**
  - **CORIST**
    - First 12-patient cohort finalized
    - Green light received from DSMB to continue with next cohort
    - Important upcoming clinical read-out in Q2, 2021
  - **PANTAX**
    - Amendment submitted to the DMA, based on the learnings obtained from the first 12 patient cohort in CORIST
- **Strengthening of the organization**
  - New hires on all levels
  - COO, CAB
- **Professionalized communication and IR**
  - Capital Market Day planned
  - Analyst coverage planned
- **Change of listing to Nasdaq First North GM**



# Scandion Oncology - at a glance

## OUR VISION

*To overcome cancer drug resistance in order to improve lives for cancer patients and their families*



### 2 Clinical Programs

1 Phase II, 1 Phase Ib



### Pipeline

SCO-101, SCO-201, 800 analogues



### Cancer Indications

Colorectal, Pancreatic, Breast and others



### Experience

Significant experience in medical oncology and pharmaceutical development



### People

12 employees  
Office in Copenhagen, DK



### Listed Stock Exchange

Nasdaq First North Stockholm



**150** MDKK

Cash position primo 2021

**470** MDKK

Market cap April 19, 2021



The Cancer Drug Resistance Company

# Developing First-in-class add-on Drugs Targeting Cancer Drug Resistance



Anti-cancer therapies



SCO-101



Addressing cancer drug resistance to complement standard anti-cancer therapies

- By adding SCO-101, the aim is to offer **an improved response rate and increased survival time for cancer patients with drug resistant tumors**
- The current pipeline targets approximately 60% of currently used chemotherapies
- Initially, the company is targeting colorectal-, pancreatic- and breast cancer


SCO-101 has the potential to quickly reach peak sales

- **SCO-101 will be subscribed together with the most commonly used anti-cancer therapies**
- Potential to be used in combination with first line anti-cancer therapy
- The mechanisms of action are enabling the company to target a wide variety of cancer indications – potentially increasing the addressable market






# SCO-101 can be added in early stage- and metastatic cancer

SCO-101 has the potential to stop the progression of drug resistant cancer cells that survive chemotherapy treatment



SCO-101 in combination with chemotherapy eradicates drug resistant cancer cells




 Drug resistant cancer cells  
 Drug sensitive cancer cells





# SCO-101 works in synergy with paclitaxel



Source: Preclinical data results



# Clinical Pipeline

*Developing first-in-class medicines for personalized therapy*

PROGRAM/ INDICATION	COMPOUND	PHASE	2020	2021	2022	2023
<b>CORIST:</b> Drug resistant metastatic colorectal cancer	SCO-101	Phase II part 1	[Teal arrow spanning 2020 to mid-2021]			
		Phase II part 2		[Teal arrow spanning mid-2021 to mid-2022]		
<b>PANTAX:</b> Inoperable or metastatic pancreatic cancer	SCO-101	Phase Ib	[Dark teal arrow spanning late 2020 to mid-2021]			
		Phase II		[Dark teal arrow spanning mid-2021 to late 2023]		
Biomarker development and clinical validation	SCO-101		[Light grey arrow spanning 2020 to late 2023]			



# Expected Significant Events 2021


## CORIST



### Q2 2021

- Data read-out part 1 of Phase II study
- Initiate part 2 of Phase II study

## Immuno-oncology



### Q2 2021

- Read-out from the preclinical collaboration with Alligator Bioscience AB

## PANTAX



### Q3-Q4 2021

- Data read-out Phase Ib study
- Initiate application for randomized Phase II study


Financing secured until at least after 2022



The Cancer Drug Resistance Company



# Strategy to Develop Innovative First-in-class Drugs



*Targeting partnerships and licensing agreements post clinical Phase II trials*



# Leadership – Track Record of Successfully Developing Biotechnology Companies



**Bo Hansen**  
President and CEO

**Maj Hedtjärn**  
COO and Head of R&D Ops

**Carit Andersen**  
CFO

**Peter Vestlev**  
CMO

**Jan Stenvang**  
CTO and Co-founder

**Nicklas Roest**  
CRO

**Annie Rasmussen**  
CCO

- Seasoned top executive and life science entrepreneur
- Previously CEO of Genevant Sciences, Global Head & GM Roche, former executive in Santaris Pharma (acq. by Roche, USD 450m)
- Holdings: 25.173 shares and 1.071.688 warrants

- 15+ years of R&D and leadership experience from international and Scandinavian pharma and biotech (Roche, Santaris Pharma, Lundbeck)

- Former CFO of AstraZeneca A/S, Denmark
- +15 years of experience in finance and biotech
- Holdings: 65.360 shares and 53.584 warrants

- Medical oncologist with experience from regulatory issues regarding cancer drugs
- Vast experience from leading clinical trials
- Holdings: 140.297 shares and 53.584 warrants

- Broad experience in cancer resistance mechanisms and clinical work in several companies
- Holdings: 1,391,064 shares

- Broad experience in drug development spanning from preclinical to early and late stage projects
- Holdings: 30.688 shares and 53.585 warrants

- Extensive oncology clinical research & operational experience from Oncology Clinics & Research Units
- Co-founder of Topotarget A/S, Founder of HealthCreationDK and CancerGuidesDK
- Holdings: 18.795 shares and 53.585 warrants



The Cancer Drug Resistance Company



# Why Invest in Scandion Oncology?

## Targeting Cancer Drug Resistance

rapid peak sales can be reached given a combination therapy application

Scandion Oncology A/S is a clinical Phase II biotechnology company developing **first-in-class, oral, add-on drugs to revert resistance to existing anti-cancer therapies.**

**Targeting USD 37bn chemotherapy market growing at 12% annually**

## Well-documented Mechanisms of Action

enabling the company to target a wide variety of cancer indications

**Lead candidate, SCO-101, currently in clinical Phase II trial (CORIST) targeting metastatic chemotherapy resistant colorectal cancer. Data read-out from part 1 in Q2, 2021**

**A Phase Ib trial (PANTAX) targeting metastatic pancreatic cancer with expected data read-out in Q3-Q4, 2021**

## Experienced Leadership

track record of successfully developing biotechnology companies

Proven track-record of preclinical research, clinical trials and deal activities paves the way for **future commercial success whilst reducing execution risk**



# Q&A

## **Investor Relations:**

Bo Rode Hansen, President & CEO

Email: [ir@scandiononcology.com](mailto:ir@scandiononcology.com)

Phone: +45 38 10 20 17



**Sign up to Scandion news on  
our website:**

**[www.scandiononcology.com](http://www.scandiononcology.com)**



**The Cancer Drug Resistance Company**